177 related articles for article (PubMed ID: 31248461)
1. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients. Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461 [TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. J Immunother Cancer; ; . PubMed ID: 34413169 [TBL] [Abstract][Full Text] [Related]